Overview
The major objective of this project is to examine whether daily consumption of milk polar lipids (MPLs) influences cardiometabolic risk factors.
Description
The investigators will conduct a randomized, double-blind, controlled, parallel, intervention study in dyslipidemic adults with abdominal obesity (n = 130). Participants will consume either a control dairy beverage (n = 65) or an MPL-rich dairy beverage (n = 65) for 8 weeks. The investigators plan to evaluate the following 4 specific objectives:
- Determine the effects of MPLs on serum lipid concentrations and other cardiometabolic risk factors.
- Evaluate the effects of MPLs on systemic biomarkers of low-grade inflammation.
- Examine the effects of MPLs on lipoprotein metabolism and lipoprotein particle characteristics.
- Evaluate the effects of MPLs on gut microbiota, gut permeability markers, and fecal lipids.
Eligibility
Inclusion Criteria:
- LDL-C ≥ 130 mg/dL
- Waist circumference ≥ 88 cm for women, ≥ 102 cm for men
- Aged 18 to 70 years
Exclusion Criteria:
- Renal disease
- Liver disease
- Diabetes
- Heart disease
- Stroke
- Cancer
- Eating disorders
- Thyroid disease
- Gut-associated pathologies
- Autoimmune diseases
- Chronic inflammatory diseases
- Scleroderma
- Gallbladder disease
- Blood clotting disorders
- Intravenous drug use
- Fasting plasma/serum triglycerides >500 mg/dL
- Fasting plasma/serum glucose >126 mg/d
- Weight changes >10% over last 4 weeks
- Oral antibiotics use up to 1 month prior to and during study
- Allergy or intolerance to milk products
- Taking lipid-lowering medications (e.g., statins, fibrates)
- Taking anti-inflammatory medications (e.g., corticosteroids)
- Taking medications which primarily affect blood clotting (e.g., warfarin).